Together, our results provide a comprehensive transcriptomic overview and reveal novel intercellular crosstalks between CD36+ CAFs, CD33+ MDSCs and HCC cells, suggesting a potential microenvironment-targeting combination therapy for HCC. The gene discussed is CD33; the disease is hepatocellular carcinoma.